Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Talphera (TLPH)
NASDAQ:TLPH
Talphera (TLPH) Stock Price & Analysis
1,910 Followers
TLPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.43 - $1.61
Previous Close$0.92
Volume22.39K
Average Volume (3M)69.35K
Market Cap
$15.63M
Enterprise Value$2.24M
Total Cash (Recent Filing)$13.39M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Aug 08, 2024EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.89
Shares Outstanding16,992,977
10 Day Avg. Volume96,213
30 Day Avg. Volume69,352
Standard Deviation0.23
R-Squared0.00624
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)1.66
Price to Sales (P/S)62.66
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.61
Enterprise Value/Gross Profit-2.74
Enterprise Value/Ebitda-1.36
Forecast
1Y Price Target
$4.50Price Target Upside389.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Talphera News
PremiumCompany Announcements
Talphera Shareholders Affirm Leadership and Financial Strategy
PremiumCompany Announcements
Talphera, Inc. Is Worried About This – Should You Be Worried Too?
Bulls Say, Bears Say
Bulls Say
Financial SupportManagement noted that Nantahala Capital, a lead investor of Talphera, has committed to provide the necessary financial support for Niyad's first approval.
Product PotentialOverall, positive sentiment remains on Niyad (nafamostat) and its potential as a regional anticoagulant for the extracorporeal circuit (ECC).
Regulatory AdvantageNiyad already has Breakthrough Therapy Designation and may receive a 6-month priority review.
Bears Say
Clinical TrialsTalphera announced a delay in the Niyad Phase 3 NEPHRO CRRT trial enrollment.
Financial PerformanceTopline results are no longer expected in 3Q24, with management planning to provide an update on timelines.
Market ProjectionA 3-month delay in Niyad's time to market is currently projected.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TLPH FAQ
What was Talphera’s price range in the past 12 months?
Talphera lowest stock price was $0.42 and its highest was $1.61 in the past 12 months.
What is Talphera’s market cap?
Currently, no data Available
When is Talphera’s upcoming earnings report date?
Talphera’s upcoming earnings report date is Aug 08, 2024 which is in 35 days.
How were Talphera’s earnings last quarter?
Talphera released its earnings results on May 14, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.25 by $0.09.
Is Talphera overvalued?
According to Wall Street analysts Talphera’s price is currently Undervalued.
Does Talphera pay dividends?
Talphera does not currently pay dividends.
What is Talphera’s EPS estimate?
Talphera’s EPS estimate is -$0.21.
How many shares outstanding does Talphera have?
Talphera has 16,992,977 shares outstanding.
What happened to Talphera’s price movement after its last earnings report?
Talphera reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.25. Following the earnings report the stock price went up 19.608%.
Which hedge fund is a major shareholder of Talphera?
Currently, no hedge funds are holding shares in TLPH
---
Talphera Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (389.13% Upside)
$4.50 (389.13% Upside)
Insider Transactions
Bought Shares
Worth $9.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.11%
12-Months-Change
Fundamentals
Return on Equity
-93.57%
Trailing 12-Months
Asset Growth
9.43%
Trailing 12-Months
Company Description
Talphera
AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. Its products include sufentanil, DZUVEO, DSUVIA ZALVISO US and ZALVISO EU. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.
---
TLPH Earnings Call
Q1 2024
0:00 / 0:00
---
TLPH Stock 12 Month Forecast
Average Price Target
$4.50
▲(389.13% Upside)
Technical Analysis
Best Analysts Covering TLPH
1 Year
1 Year Success Rate
5/16 ratings generated profit
1 Year Average Return
-18.88%
reiterated a buy rating 2 months ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 31.25% of your transactions generating a profit, with an average return of -18.88% per trade.
---